"The initial Phase 3 study is in amyloidosis patients, with additional Phase 3 studies in multiple myeloma and smoldering myeloma patients planned for near-term initiation."
It's not spelled out but I wonder if Halo will get a $15M milestone payment for each Phase 3 trial.
News 
Market Data 
Discover 
